Cardiology
RSSArticles
-
Early Data on Remdesivir for Severe COVID-19: A Promising Start?
In this group of patients hospitalized with severe COVID-19, the majority of whom required invasive ventilation, 68% showed clinical improvement after treatment with remdesivir on a compassionate-use basis.
-
Anticoagulation Therapy in Patients with Severe COVID-19
In a retrospective study involving 449 patients with severe COVID-19 requiring intensive care unit admission, those patients with a positive sepsis coagulation score or D-dimer greater than 3.0 mcg/mL who received prophylactic doses of low molecular weight heparin exhibited lower 28-day mortality.
-
Managing COVID-19 Respiratory Failure: Is There a Perfect Management Strategy?
COVID-19 is a systemic disease that primarily injures the vascular endothelium, causing a unique lung injury in which different management strategies may need to be considered to address the specific physiology of each patient.
-
Group Leads Charge Against Venous Thromboembolism
The American Heart Association issues guidance to help prevent a common and costly hospital-acquired condition.
-
MUCH Ado About WUCH
In a long-term, fixed-drug therapy of hypertension study, masked uncontrolled and white coat uncontrolled hypertension exhibited poor reproducibility over four years. This calls into question studies showing higher rates of adverse outcomes with one baseline blood pressure assessment used to categorize patients.
-
Thin Evidence Supporting the Obesity Paradox in STEMI
This largest-to-date analysis of six randomized studies of ST-elevation myocardial infarction revealed no association between body mass index and infarct size, one-year mortality, or heart failure hospitalization.
-
Benefits of Exercise in Established Atrial Fibrillation
A large, long-term, prospective, Norwegian population study of patients with established atrial fibrillation revealed physical activity at or above recommended levels reduces all-cause and cardiovascular mortality vs. atrial fibrillation patients who are inactive.
-
Warfarin vs. DOAC for Left Ventricular Thrombi
A large, multicenter, observational study of the relative efficacy of warfarin vs. direct oral anticoagulants (DOACs) for left ventricular thrombi has shown that DOAC use is associated with a higher risk of embolic events than warfarin. Investigators advised caution with off-label use of DOACs.
-
Does Anticoagulant Therapy Affect Outcomes in Left Ventricular Mural Thrombus Patients?
Left ventricular thrombus is an uncommon finding but one associated with a high incidence of all-cause mortality and major adverse cardiac and embolic events. Total regression of left ventricular thrombus on anticoagulant therapy reduced mortality.
-
Acute Myocardial Infarction, or Acute Pericarditis?
The lack of significant Q waves, lack of any reciprocal ST depression, and the prominent J-point notching in the figure all suggest this may not be an acute infarction.